|
KMID : 0578320190420020161
|
|
Molecules and Cells
2019 Volume.42 No. 2 p.161 ~ p.165
|
|
|
TGFBI Promoter Methylation is Associated with Poor Prognosis in Lung Adenocarcinoma Patients
|
|
Seok Yang-Ki
Lee Won-Kee
Park Jae-Yong
Kim Dong-Sun
|
|
|
Abstract
|
|
|
|
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide and has high rates of metastasis. Transforming growth factor beta-inducible protein (TGFBI) is an extracellular matrix component involved in tumour growth and metastasis. However, the exact role of TGFBI in NSCLC remains controversial. Gene silencing via DNA methylation of the promoter region is common in lung tumorigenesis and could thus be used for the development of molecular biomarkers. We analysed the methylation status of the TGFBI promoter in 138 NSCLC specimens via methylation-specific PCR and evaluated the correlation between TGFBI methylation and patient survival. TGFBI promoter methylation was detected in 25 (18.1%) of the tumours and was demonstrated to be associated with gene silencing. We observed no statistical correlation between TGFBI methylation and clinicopathological characteristics. Univariate and multivariate analyses showed that TGFBI methylation is significantly associated with poor survival outcomes in adenocarcinoma cases (adjusted hazard ratio = 2.88, 95% confidence interval = 1.19?6.99, P = 0.019), but not in squamous cell cases. Our findings suggest that methylation in the TGFBI promoter may be associated with pathogenesis of NSCLC and can be used as a predictive marker for lung adenocarcinoma prognosis. Further large-scale studies are needed to confirm these findings.
|
|
|
KEYWORD
|
|
|
Hypermethylation, MSP, NSCLC, Prognosis, TGFBI
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|